12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients

PHASE3TerminatedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

July 27, 2018

Study Completion Date

July 27, 2018

Conditions
PTSD
Interventions
DRUG

TNX-102 SL

2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks

Trial Locations (32)

10128

New York, New York

11516

Cedarhurst, Cedarhurst

29407

Charleston, Charleston

30341

Atlanta, Atlanta

32256

Jacksonville, Jacksonville

32607

Lake City, Lake City

33319

Lauderhill, Lauderhill

33609

Tampa, Tampa

39232

Flowood, Flowood

44718

Canton, Canton

45219

Cincinnati, Cincinnati

45417

Dayton, Dayton

72758

Rogers, Rogers

73103

Oklahoma City, Oklahoma City

75231

Dallas, Dallas

77098

Houston, Houston

78229

San Antonio, San Antonio

78754

Austin, Austin

80910

Colorado Springs, Colorado Springs

85032

Phoenix, Phoenix

89102

Las Vegas, Las Vegas

90210

Beverly Hills, Beverly Hills

91206

Glendale, Glendale

92056

Oceanside, Oceanside

92123

San Diego, San Diego

92161

San Diego, San Diego

92506

Riverside, Riverside

92591

Temecula, Temecula

92868

Orange, Orange

94607

Oakland, Oakland

02740

New Bedford, New Bedford

08009

Berlin, Berlin

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT03110575 - 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients | Biotech Hunter | Biotech Hunter